BCM
VBIV

BlueCrest Capital Management’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

BlueCrest Capital Management’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,727
Closed -$125K – 1497
2018
Q3 		$125K Sell
1,727
-5,001
-74% -$330K ﹤0.01% 1361
2018
Q2 		$555K Buy
+6,728
New +$650K 0.01% 774

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

BlueCrest Capital Management's VBIV Position: Q4 2018 in Review

BlueCrest Capital Management sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q4 2018, closing a stake of 1,727 shares — an estimated $125K sold.

BlueCrest Capital Management first reported a position in VBIV in Q2 2018 and held it in 2 quarters. The position peaked at $555K in Q2 2018. 40 funds tracked by Wall St. Rank hold VBIV as of Q4 2018.

  • BlueCrest Capital Management reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 1,727 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q4 2018, an estimated $125K.
  • BlueCrest Capital Management first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $555K in Q2 2018.
  • 40 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.